Telix has much more tiger in the tank – analysts
Broking analysts have raised their valuation of Telix Pharmaceuticals shares after the company’s bullish update.
Stockhead
Long Shortz with Optiscan Imaging
Dr Camile Farah joins Fraser Palamara on Stockhead TV
Final stages of FDA approval for EBR
EBR Systems joins Fraser Palamara on Stockhead TV to talk about its final stages of FDA approval.
Meteoric’s low costs to weather rare earths storms
Today’s rare earths market may be tough, but once up and running Meteoric’s Caldeira project in Brazil will be able to weather the storm.
More Stories
Challenger’s toll gold plant in shape
Toll Milling offers Challenger Gold a direct route to early production, allowing the company to generate cashflow to support the Hualian gold project.
Rio goes all in on lithium
Rio Tinto has reinforced its conviction lithium prices will rebound, pledging US$2.5bn ($3.9bn) to build the 60,000tpa Rincon project in Argentina.
Road to 2025: EE1
Sarah looks at Earths Energy and its geothermal advancements as it looks toward entrenching itself as a globally relevant power producer.
Road to 2025: AZL
Stockhead looks at Arizona Lithium and its progress towards first production at its Prairie lithium project in Saskatchewan, Canada.
IML fundie believes Hipages is undervalued
As the tradies market embraces digitalisation, Hipages is positioning itself to capitalise and capture the $141 billion local industry.
UVA polishes up yellowcake prospects
Uvre is refining multiple South Australian uranium targets as it looks ahead to drilling in 2025.
2025 IPO hopeful tackling global “infant killer”
Slated to list on the ASX next year, Nexsen Biotech has developed a simple device to diagnose the infant killer group B streptococcus.
Net zero goals still need hydrogen
Heavy transport and displacing fossil fuel-derived hydrogen are some of the key areas where clean hydrogen can shine.
Original URL: https://www.couriermail.com.au/business/stockhead/page/200